drugset / Trial / NCT02034019

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019 ↗

Phase 3 Completed 247 enrolled Ocular Therapeutix, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.

Timeline

Start
2014-02
Primary completion
2014-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule — Other

Indications

No indication recorded.